Bringing Precision Medicine to Cholangiocarcinoma With Mitesh J. Borad, MD

With an estimated incidence of 8,000 new cases per year, cholangiocarcinoma is a rare and aggressive tumor type that accounts for only 3% of all gastrointestinal cancers. Outcomes are poor, with 5-year survival rates ranging from 24% to as low as 2%. In this episode of Oncology Data Advisor, Mitesh J. Borad, MD, Associate Professor of Medicine and Director of the Liver and Biliary Cancer Research Program at the Mayo Clinic Cancer Center in Phoenix, Arizona, joins i3 Health for a discussion that covers the efficacy and adverse events of FGFR inhibitor therapy, ongoing research related to additional therapeutic targets, and the increasing role of precision medicine in the treatment of patients with cholangiocarcinoma.

Related Posts

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.